OncoPrecision Corporation utilizes single-cell high-throughput biology and artificial intelligence/machine learning to enhance the efficacy of cancer therapies. The company focuses on increasing treatment success rates by providing precise insights into tumor heterogeneity and patient-specific responses.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer therapies often face challenges due to tumor heterogeneity and varying patient-specific responses, leading to suboptimal treatment outcomes. A lack of precise insights into these factors hinders the ability to tailor treatments effectively and maximize efficacy.
Solution
OncoPrecision Corporation leverages single-cell high-throughput biology and artificial intelligence/machine learning to improve the effectiveness of cancer therapies. By analyzing tumor heterogeneity at the single-cell level, the company aims to provide precise insights into how individual patients will respond to specific treatments. This approach enables a more tailored and targeted therapeutic strategy, potentially increasing treatment success rates. The company's technology seeks to overcome the limitations of traditional methods by offering a deeper understanding of the complex interplay between cancer cells and therapeutic interventions.
Target Audience
The primary customers are oncologists, pharmaceutical companies, and research institutions seeking to enhance cancer treatment efficacy through personalized medicine approaches.
Features
- Single-cell resolution analysis of tumor samples
- High-throughput biological assays for comprehensive data acquisition
- AI/ML-powered predictive modeling of patient-specific treatment responses